Search or
𝛼SK
𝛼SKbullish
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation
In Sept. 2024, WINT reported positive Phase 2b study results of istaroxime in early CS patients. To position istaroxime for Phase 3 readiness,...
What is covered in the Full Insight:
- Introduction to Windtree Therapeutics
- Overview of Istaroxime and its Market
- New Strategic Direction Under CEO Jed Latkin
- Recent Financial Performance and Market Outlook
- Conclusion and Forward-looking Statements
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 26-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Loading...
x